Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PULMBullishM&Anews

High materiality8/10

Pulmatrix merger progress with Eos SENOLYTIX near-term catalyst and cash runway

Aug 13, 2026, 8:18 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The S-4 filing and stated Q3 2026 close create a tangible near-term catalyst; potential upside from monetizing assets and international rights, offset by execution risk and going-concern notes.

AI summary

What happened, with direct paths to the underlying reporting

Pulmatrix announced Q2 2026 results and an update on its merger with Eos SENOLYTIX, aiming for closing in Q3 2026. The company reported $2.2 million in cash and $0.7 million in restricted cash, with all clinical development on hold pending asset monetization. Key catalysts include PUR1900's India Phase 3 with Cipla and potential international royalties from PUR1900, plus overall merger-related value realization.

Pulmatrix filed Form S-4 for merger with Eos SENOLYTIX.
Merger expected to close in Q3 2026; business to continue with combined entity.
Q2 2026 results show R&D paused; monetization/licensing of assets pursued.
Series B convertible preferred raised $1.0 million gross; affiliate of Eos involved.
PUR1900 Phase 3 in India with Cipla; 2% royalties outside US; PUR3100/1800 updates.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.